Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.53 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL10948372 | 0.87 | LTA4H (0.54) | LTA4HANPEPRNPEPDNPEPSLC1A3 | |
| Leucine SCHEMBL10956565 | 0.87 | LTA4H (0.54) | LTA4HANPEPRNPEPDNPEPSLC1A3 | |
| Leucine SCHEMBL8740479 | 0.85 | LTA4H (0.60) | LTA4HANPEPRNPEPDNPEPSLC1A3 | |
| SCHEMBL1272029 | 0.84 | NAALAD2 (0.55) | MME | |
| SCHEMBL547297 | 0.84 | NAALAD2 (0.55) | MME | |
| SCHEMBL547710 | 0.84 | NAALAD2 (0.55) | MME | |
| Leucine SCHEMBL8019054 | 0.84 | LTA4H (0.59) | LTA4HANPEPRNPEPDNPEPSLC1A3 | |
| SCHEMBL9340320 | 0.83 | NAALAD2 (0.54) | MME | |
| Leucine SCHEMBL28279047 | 0.83 | LTA4H (0.52) | LTA4HANPEPRNPEPDNPEPSLC1A3 | |
| SCHEMBL3910340 | 0.82 | MME (0.66) | LTA4HACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030012817-A1 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES, INC. | 2003-01-16 | — | — | US | claimed |
| US-20020052422-A1 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES, INC. | 2002-05-02 | — | — | US | claimed |
| EP-0696208-B1 | ORAL DRUG DELIVERY COMPOSITIONS | EMISPHERE TECH INC (US) | 2001-08-22 | — | — | EP | claimed |
| EP-1077070-A2 | Oral drug delivery compositions | Emisphere Technologies, Inc. (US) | 2001-02-21 | — | — | EP | claimed |
| US-5792451-A | AMINO ACID DERIVATIVES AS CARRIERS FOR SENSITIVE AGENTS SUCH AS BIOACTIVE PEPTIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-08-11 | — | — | US | claimed |
| US-5766633-A | MODIFIED AMINO ACID CARRIER, BIOACTIVE PEPTIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-06-16 | — | — | US | claimed |
| EP-0696208-A4 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECH INC (US) | 1997-01-29 | — | — | EP | claimed |
| EP-0696208-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | Emisphere Technologies, Inc. (US) | 1996-02-14 | — | — | EP | claimed |
| WO-1994023767-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECHNOLOGIES, INC. (US) | 1994-10-27 | — | — | WO | claimed |
| US-20060134130-A1 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| US-7005141-B2 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES INC. (US) | 2006-02-28 | — | — | US | disclosed |
| EP-1025840-B1 | Oral drug compositions | EMISPHERE TECH INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20030012817-A1 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6461643-B2 | CONSISTS OF AT LEAST ONE BIOLOGICALLY- ACTIVE AGENT; (B) AT LEAST ONE CARRIER COMPRISING AN ACYLATED ALDEHYDE OF AN AMINO ACID, AN ACYLATED KETONE OF AN AMINO ACID, AN ACYLATED ALDEHYDE OF A PEPTIDE, AN ACYLATED KETONE OF A PEPTIDE | EMISPHERE TECHNOLOGIES, INC. | 2002-10-08 | — | — | US | disclosed |
| US-5792451-A | AMINO ACID DERIVATIVES AS CARRIERS FOR SENSITIVE AGENTS SUCH AS BIOACTIVE PEPTIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5766633-A | MODIFIED AMINO ACID CARRIER, BIOACTIVE PEPTIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0696208-A4 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECH INC (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0696208-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | Emisphere Technologies, Inc. (US) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994023767-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECHNOLOGIES, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| US-4513009-A | GLYCINE, ALANINE AND SERINE DERIVATIVES | SOCIETE CIVILE BIOPROJET (FR) | 1985-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030012817-A1 | Oral drug delivery compositions and methods | PTMS, ADM2, DNPEP | LTA4H 1785/4885ANPEP 14/4885RNPEP 218/4885 |
| US-20060134130-A1 | Oral drug delivery compositions and methods | ADM2, PTMS, DNPEP | LTA4H 2303/4885ANPEP 26/4885RNPEP 216/4885 |
| US-20020052422-A1 | Oral drug delivery compositions and methods | ADM2, PTMS, DNPEP | LTA4H 2303/4885ANPEP 26/4885RNPEP 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.